Therapeutic effects of autologous hematopoietic stem cell transplantation in multiple myeloma patients

Fu,Chengcheng; Wang,Juan; Xin,Xue; Liu,Hui; Xue,Shengli; Ma,Xiao; Jin,Zhengming; Sun,Aining; Qiu,Huiying; Wu,Depei

doi:10.3892/etm.2013.1261

October 2013 Volume 6 Issue 4

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

October 2013 Volume 6 Issue 4

Full Size Image

Article

Therapeutic effects of autologous hematopoietic stem cell transplantation in multiple myeloma patients

Authors:
- Chengcheng Fu
- Juan Wang
- Xue Xin
- Hui Liu
- Shengli Xue
- Xiao Ma
- Zhengming Jin
- Aining Sun
- Huiying Qiu
- Depei Wu
View Affiliations / Copyright

Affiliations: Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis, Ministry of Health, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China
Pages: 977-982
|
Published online on: August 16, 2013

https://doi.org/10.3892/etm.2013.1261
Expand metrics +

Abstract

The present study aimed to evaluate the effect of autologous hematopoietic stem cell transplantation (ASCT) on the response and outcome of patients with multiple myeloma (MM) and to analyze the factors influencing the prognosis of the disease. Retrospective analysis was performed in 27 patients with MM who had been treated by ASCT (ASCT group) and 28 patients treated with combined chemotherapy only (non-ASCT group) from May 2004 to August 2011. The impact on the depth of response, progression‑free survival (PFS) and overall survival (OS) times, as well as associated prognostic factors of patients with MM, were analyzed. All patients successfully underwent hematopoietic reconstruction without transplantation‑related mortality. The complete remission (CR) rate of patients in the ASCT group significantly increased from 25.9% (7/27) before ASCT to 70.4% (19/27) following ASCT (P<0.01). The probability of OS for 5 years was 52.2% for the patients in the ASCT group and 33.1% for those in the non‑ASCT group (P>0.05). Univariate analysis in the ASCT group demonstrated that maintenance and consolidation therapies were associated with significant increases in PFS (P=0.01) and OS (P<0.01) times. The present study demonstrated that ASCT further increases the CR rate, prolongs PFS time and potentially increases the OS time. Incorporation of these novel agents, including the proteasome inhibitor bortezomib and the immunomodulatory drugs thalidomide and lenalidomide, into the induction, consolidation and maintenance phases has optimized the anti‑myeloma activity of ASCT.

View Figures

View References

1.	Kyle RA and Rajkumar SV: Multiple myeloma. New Engl J Med. 351:1860–1873. 2004. View Article : Google Scholar
2.	Talamo G, Farooq U, Zangari M, et al: Beyond the CRAB symptoms: a study of presenting clinical manifestations of multiple myeloma. Clin Lymphoma Myeloma Leuk. 10:464–468. 2010. View Article : Google Scholar : PubMed/NCBI
3.	Myeloma Trialists’ Collaborative group: Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials. J Clin Oncol. 16:3832–3842. 1998.PubMed/NCBI
4.	Bladé J, Rosiñol L, Cibeira MT, Rovira M and Carreras E: Hematopoietic stem cell transplantation for multiple myeloma beyond 2010. Blood. 115:3655–3663. 2010.PubMed/NCBI
5.	Anderson KC, Alsina M, Bensinger W, et al: Multiple myeloma. J Natl Compr Canc Netw. 9:1146–1183. 2011.
6.	Brenner H, Gondos A and Pulte D: Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood. 111:2521–2526. 2008. View Article : Google Scholar : PubMed/NCBI
7.	Lahuerta JJ, Mateos MV, Martínez-López J, et al: Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol. 26:5775–5782. 2008. View Article : Google Scholar : PubMed/NCBI
8.	Barlogie B, Tricot G, Anaissie E, et al: Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 354:1021–1030. 2006. View Article : Google Scholar : PubMed/NCBI
9.	Barlogie B, Pineda-Roman M, van Rhee F, et al: Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood. 112:3115–3121. 2008. View Article : Google Scholar
10.	Harousseau JL and Moreau P: Autologous hematopoietic stem-cell transplantation for multiple myeloma. N Engl J Med. 360:2645–2654. 2009. View Article : Google Scholar : PubMed/NCBI
11.	van de Velde HJ, Liu X, Chen G, Cakana A, Deraedt W and Bayssas M: Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica. 92:1399–1406. 2007.PubMed/NCBI
12.	Harousseau JL, Attal M, Avet-Loiseau H, et al: Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: Results of the IFM 2005-01 phase III trial. J Clin Oncol. 28:4621–4629. 2010. View Article : Google Scholar
13.	Cavo M, Zamagni E, Tosi P, et al: Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood. 106:35–39. 2005. View Article : Google Scholar : PubMed/NCBI
14.	Moreau P, Facon T, Attal M, et al: Comparison of reduced-dose bortezomib plus thalidomide plus dexamethasone (vTD) to bortezomib plus dexamethasone (VD) as induction treatment prior to ASCT in de novo multiple myeloma (MM): Results of IFM2007-02 study. J Clin Oncol. 28(Suppl 15): A80142010.
15.	Richardson PG, Weller E, Lonial S, et al: Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 116:679–686. 2010. View Article : Google Scholar : PubMed/NCBI
16.	Roussel M, Moreau P, Huynh A, et al: Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: A phase 2 study of the Intergroupe Francophone du Myelome (IFM). Blood. 115:32–37. 2010. View Article : Google Scholar : PubMed/NCBI
17.	Harousseau JL, Attal M and Avet-Loiseau H: The role of complete response in multiple myeloma. Blood. 114:3139–3146. 2009. View Article : Google Scholar : PubMed/NCBI
18.	Niesvizky R, Richardson PG, Rajkumar SV, et al: The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. Br J Haematol. 143:46–53. 2008. View Article : Google Scholar
19.	Harousseau JL, Weber D, Dimopoulos M, et al: Relapsed /refractory multiple myeloma treated with lenalidomide/dexamethasone who achieve a complete or near complete response have longer overall survival and time to progression compared with patients achieving a partial response. Blood. 110:35982007.
20.	Pineda-Roman M, Zangari M, Haessler J, et al: Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J Haematol. 140:625–634. 2008. View Article : Google Scholar : PubMed/NCBI
21.	Spencer A, Prince HM, Roberts AW, et al: Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol. 27:1788–1793. 2009. View Article : Google Scholar
22.	Attal M, Harousseau JL, Leyvraz S, et al: Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood. 108:3289–3294. 2006. View Article : Google Scholar : PubMed/NCBI
23.	Moreau P, Avet-Loiseau H, Harousseau JL and Attal M: Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies. J Clin Oncol. 29:1898–1906. 2011. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Therapeutic effects of autologous hematopoietic stem cell transplantation in multiple myeloma patients

This article is mentioned in:

Abstract

Figure 1

Figure 2

Related Articles